CSAG family member 2Genealiases: CSAG3B · CT24.2 · TRAG-3 · TRAG3
Q-omics provides the consensus-scored CSAG2 profile across patient tissues and cancer cell-line models. CSAG2 expression is associated with patient survival in 23 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, CSAG2 is differentially expressed in 8, with the highest sampling consensus in HNSC. Additionally, CSAG2 RNA expression shows 6,395 significant pathway-activity associations, with the highest sampling consensus in SKCM. Together, these results highlight KIRC, HNSC, and SKCM as cancer lineages where CSAG2 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for CSAG2 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes CSAG2 survival associations across molecular data types. CSAG2 RNA expression shows survival associations in the most cancer types (23), followed by mutation status (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible CSAG2 RNA expression–survival associations across cancer types. High CSAG2 expression shows unfavorable associations in KIRC, ACC, LIHC and KICH, but favorable associations in BLCA and ESCA. The KIRC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for CSAG2 RNA expression.
This table summarizes CSAG2 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8. The strongest signals are observed in HNSC for RNA.
This table ranks reproducible tumor–normal expression differences for CSAG2. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. CSAG2 shows lower tumor expression in KIRP and higher tumor expression in HNSC, LIHC, STAD, LUSC and BRCA. The HNSC box plot shows higher CSAG2 RNA expression in tumor versus normal tissue (log2 FC = +1.761, t-test p < 0.001).
This table shows molecular features associated with CSAG2 in patient tissues and cancer cell lines. In patient samples, CSAG2 shows the broadest associations at the RNA and protein expression levels, with SKCM recurring as the lineage with the largest associated feature set.
